Vivos Therapeutics
VVOS
30 hedge funds and large institutions have $1.38M invested in Vivos Therapeutics in 2022 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 2 closing their positions.
150% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 2
11% more funds holding
Funds holding: 27 → 30 (+3)
0.01% less ownership
Funds ownership: 0.38% → 0.37% (-0.01%)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
51% less capital invested
Capital invested by funds: $2.82M → $1.38M (-$1.44M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$63.5K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$50.5K |
| 3 |
AF
Apexium Financial
Dallas,
Texas
|
+$49.6K |
| 4 |
SWM
SeaCrest Wealth Management
Purchase,
New York
|
+$48.7K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$44.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BRWA
B. Riley Wealth Advisors
Boca Raton,
Florida
|
-$131K |
| 2 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$131K |
| 3 |
Boston Partners
Boston,
Massachusetts
|
-$55.7K |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$55.7K |
| 5 |
VF
Virtu Financial
New York
|
-$15K |
VVOS Hedge Fund Activity: Q3 2022 in Review
30 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Vivos Therapeutics (VVOS) for Q3 2022, worth a combined $1.38M — down 51% from $2.82M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new VVOS positions and 2 closed out — a net gain of 3 holders — while 4 added to existing stakes and 8 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $63.5K. The largest seller was B. Riley Wealth Advisors, exiting entirely with an estimated $131K sold.
- 30 institutional investors held Vivos Therapeutics (VVOS) as of Q3 2022, up from 27 in Q2 2022.
- Funds reported $1.38M of Vivos Therapeutics stock for Q3 2022, down 51% quarter-over-quarter.
- 5 funds opened new Vivos Therapeutics positions in Q3 2022 and 2 closed out, a net change of +3 holders.
- The largest Vivos Therapeutics buyer in Q3 2022 was Citadel Advisors, an estimated $63.5K added.
- The largest Vivos Therapeutics seller in Q3 2022 was B. Riley Wealth Advisors, an estimated $131K sold.
Based on aggregated 13F filings for Q3 2022.